News

Press Release Issued:
IASIC Opposes the Removal of Cannabis from Schedule 1

BURLINGTON, Vermont – June 25, 2024 – The International Academy on the Science and Impact of Cannabis (IASIC) released its official statement against the proposed rescheduling of Cannabis from Schedule I to Schedule III of the Controlled Substances Act:

As physicians and concerned citizens of the United States of America, the International Academy on the Science and Impact of Cannabis believes that re-scheduling will have immediate and irreparable harm to the public health and vehemently oppose the removal of cannabis from Schedule 1. Specific objections include (1) The Department of Health and Human Services (HHS) inappropriately changed the definition of currently acceptable medical use (CAMU); (2) Even under the new definition, cannabis still does not meet the requirements for CAMU; (3) Proper regulation of cannabis as a schedule 3 drug cannot be achieved while non-medical cannabis commerce is allowed.

“HHS and those who are pushing rescheduling of cannabis are unaware or ignoring the huge amount of science on the medical harms of cannabis. There is zero benefit and only problems to be had from rescheduling,” said Eric A. Voth, MD, FACP, President and Chairman of the Board, The International Academy on the Science and Impact of Cannabis.

An official request for a hearing with the DEA has been submitted by IASIC during the current open comment period, with its leadership urging the presentation of medical and scientific research from its physician-driven organization of international experts on cannabis.

IASIC has provided substantial education and background on the impending harm of the proposed rescheduling in its monthly speaker series on June 11th as well as on the High Truths on Drugs and Addiction podcast with episode #182: High Truths on Drugs and Addiction on Rescheduling of Marijuana with IASIC.

FDA Warns Consumers About the Accidental Ingestion by Children of Food Products Containing THC

July 18, 2022 No Comments

Some manufacturers are packaging and labeling edible products containing THC to look like popular brands of commonly consumed foods, such as breakfast cereal, candy, and cookies. These products appeal to children and may be easily mistaken for popular, well-recognized foods. The FDA is aware of multiple media reports describing children and adults who accidentally consumed

Read More »

THC cannabis concentrate

July 12, 2022 No Comments

What would data-driven policy suggest regarding THC cannabis concentrate caps in Vermont and Quebec? The recent article on THC limits in cannabis concentrates leaves out the important fact that Vermont law currently includes a 60% cap on THC in solid concentrates. Thankfully, lawmakers in the Vermont House have listened to the science, and they are

Read More »

Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation

July 7, 2022 No Comments

Epidemiological studies reveal that marijuana increases the risk of cardiovascular disease (CVD); however, little is known about the mechanism. Δ9-tetrahydrocannabinol (Δ9-THC), the psychoactive component of marijuana, binds to cannabinoid receptor 1 (CB1/CNR1) in the vasculature and is implicated in CVD. A UK Biobank analysis found that cannabis was an risk factor for CVD. We found

Read More »

The phytochemical diversity of commercial Cannabis in the United States

June 23, 2022 No Comments

The legal status of Cannabis is changing, fueling an increasing diversity of Cannabis-derived products. Because Cannabis contains dozens of chemical compounds with potential psychoactive or medicinal effects, understanding this phytochemical diversity is crucial. The legal Cannabis industry heavily markets products to consumers based on widely used labeling systems purported to predict the effects of different

Read More »

What is THCP?

May 24, 2022 No Comments

THCP, which is short for tetrahydrocannabiphorol and scientifically known as (-)-Trans-Δ9-tetrahydrocannabiphorol, is a natural cannabinoid and analog of THC present in varieties of cannabis. It’s thought to be 33 times more active at cannabinoid 1 (CB1) receptors than THC, causing an intense and intoxicating euphoric high. THCP’s legality is stuck between conflicting federal legislation. It’s not

Read More »

Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults

May 16, 2022 No Comments

Key Points Question  What are the risks and benefits of obtaining a medical marijuana card for adults who seek medical marijuana for pain, insomnia, and anxiety or depressive symptoms? Findings  In this randomized clinical trial involving 186 participants, immediate acquisition of a medical marijuana card increased the incidence and severity of cannabis use disorder (CUD) and resulted

Read More »

Cannabis Contaminants Limit Pharmacological Use of Cannabidiol

May 12, 2022 No Comments

For nearly a century, Cannabis has been stigmatized and criminalized across the globe, but in recent years, there has been a growing interest in Cannabis due to the therapeutic potential of phytocannabinoids. With this emerging interest in Cannabis, concerns have arisen about the possible contaminations of hemp with pesticides, heavy metals, microbial pathogens, and carcinogenic compounds during the cultivation, manufacturing,

Read More »

First Medical Textbook on Cannabis in Medicine

Listen to podcast High Truths on Drugs and Addiction on your favorite platform. ​Hightruth.com

Most Recent News

Libby Stuyt Interview on Randy Tobler show

Exciting News! Libby Stuyt’s Interview on Randy Tobler Show! Hey everyone, we wanted to share some thrilling news! The brilliant Dr. Libby Stuyt recently had an enlightening interview on Randy Tobler Show. Dr. Stuyt is known for her groundbreaking work in the field of addiction medicine and mental health. Her insights are nothing short of

Read More »

Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies

Introduction Cannabis contains over 100 cannabinoids, of which Δ9-tetrahydrocannabinol and cannabidiol are the most clinically relevant. Tetrahydrocannabinol is a partial agonist at CB1 and binds CB2 receptors. CB1 is widely expressed by central and peripheral neurones but also by immune cells and other type of cells in the brain and in the periphery, and when

Read More »

IASIC Speaker Series Presents: Case Report on Cannabis-Induced Acute Encephalopathy in Elderly After Taking CBD

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,

Read More »
Scroll to Top